cupric iodide | 13767-71-0

• 分子结构分类: 无机化合物 - 混合金属/非金属化合物 - 过渡金属盐
• 英文名称: cupric iodide
• 英文别名: Einecs 215-625-6；copper;diiodide
• CAS: 13767-71-0
• 化学式: CuI₂
• 分子量: 317.355
• InChiKey: GBRBMTNGQBKBQE-UHFFFAOYSA-L

计算性质

• 辛醇/水分配系数(LogP)：
  1.77
• 重原子数：
  3
• 可旋转键数：
  0
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

ADMET

毒理性

• 副作用

职业性肝毒素 - 第二性肝毒素：在职业环境中的毒性效应潜力是基于人类摄入或动物实验的中毒案例。 肾毒素 - 该化学物质在职业环境中可能对肾脏有毒。 高铁血红蛋白血症 - 血液中高铁血红蛋白含量增加；该化合物被归类为第二毒性效应 溶血性贫血 - 血红蛋白或红细胞数量减少。

Occupational hepatotoxin - Secondary hepatotoxins: the potential for toxic effect in the occupational setting is based on cases of poisoning by human ingestion or animal experimentation. Nephrotoxin - The chemical is potentially toxic to the kidneys in the occupational setting. Methemoglobinemia - The presence of increased methemoglobin in the blood; the compound is classified as secondary toxic effect Hemolytic anemia - Decreased hemoglobin or number of red blood cells.

来源:Haz-Map, Information on Hazardous Chemicals and Occupational Diseases

反应信息

• 作为反应物：
  描述：

  [[(8R,9S,14S,17S)-3,17-diacetyloxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-2-yl]oxy-(2,2,2-trifluoroacetyl)oxythallanyl] 2,2,2-trifluoroacetate 、 cupric iodide 生成 [(8R,9S,14S,17S)-3-acetyloxy-2-iodo-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl] acetate
  参考文献：
  名称：

  PAGE, PHILIP C. BULMAN;HUSSAIN, FAZAL;MAGGS, JAMES L.;MORGAN, PAUL;PARK, +, TETRAHEDRON, 46,(1990) N, C. 2059-2068

  摘要：

  DOI：
• 作为产物：
  描述：

  碘化铵 生成 cupric iodide
  参考文献：
  名称：

  TANNO KAZUO; KOMANI YUMIKO; KUROSAWA FUMIO; SAITO SHIRO, INFORM. MATER. ENERGY THEORY LIFE, 54,(1986) N 6, 490-497

  摘要：

  DOI：
• 作为试剂：
  描述：

  t-butyl 4-trifluoromethanesulfonyloxy-6-azabicyclo[3.2.1]oct-3-ene-6-carboxylate 、 三乙胺 、 三甲基乙炔基硅 在 cupric iodide 、 双三苯基磷二氯化钯 、 silica gel 作用下， 以 甲苯 为溶剂， 反应 16.0h， 以to give tert-butyl 4-trimethylsilylethynyl-6-azabicyclo [3.2.1]oct-3-ene-6-carboxylate (900 mg, 58.9%)的产率得到Tert-butyl 4-trimethylsilylethynyl-6-azabicyclo[3.2.1]oct-3-ene-6-carboxylate
  参考文献：
  名称：

  PHARMACEUTICAL COMPOSITIONS AND METHODS FOR RELIEVING PAIN AND TREATING CENTRAL NERVOUS SYSTEM DISORDERS

  摘要：

  对于易感受或患有疾病的患者，例如中枢神经系统疾病，其特征为正常神经递质释放的改变，例如多巴胺释放（例如帕金森症，帕金森氏病，抽动症，注意力缺陷障碍或精神分裂症），可以通过给予本文所述的1或2式化合物来治疗。 1和2式化合物也可用于治疗疼痛，药物成瘾，尼古丁成瘾和/或肥胖症。这些化合物可以存在于单个立体异构体，混合物，对映异构体等形式。

  公开号：

  US20050282823A1

文献信息

• 1,2-disubstituted 1,4-dihydro-4-oxoquinoline compounds
  申请人：Maruishi Pharmaceutical Co., Ltd.

  公开号：US06541470B1

  公开（公告）日：2003-04-01

  The present invention relates to substituted 1,4-dihydro-4-oxoquinolines having antiviral activity. The substituents are present at positions 1, 2 and at least one of 5-8 positions of the quinoline ring.

  本发明涉及具有抗病毒活性的取代的1,4-二氢-4-氧喹啉。这些取代基位于喹啉环的1、2位置以及5-8位置中的至少一个位置。
• ⁶³Cu High Resolution NMR of Cu(I) Halides in Aqueous Solution and Suspension
  作者：Kazunaka Endo、Kyonosuke Yamamoto、Kenzo Deguchi、Kazuhiro Matsushita

  DOI：10.1246/bcsj.60.2803

  日期：1987.8

  In an aqueous solution, 63Cu chemical shielding order ([CuCl4]3− \simeq[CuBr4]3−<[CuI4]3−) and line widths (10 to 30 kHz) for CuX–KX systems(where X=Cl, Br, I) have been obtained. The chemical shift(−694 ppm) between [CuCl4]3− and [Cu(CN)4]3− is interpreted by the paramagnetic term which depends mainly upon a 3d-hole on a Cu(I) atom by using perturbation theory with an average excitation energy approximation. The linebroadening of Cu(I) halide complexes in aqueous solution is explained dominantly by a Cu(I) nuclear quadrupole interaction with the electric field gradient which arises from a 3d-hole on a Cu atom. For the abnormal increasing metal shielding order of [MX4](4−i)−([MCl4](4−i)−≤[MBr4](4−i)−<[MI4](4−i)−), a possibility of the heavyatom effect in the metal shielding of [CuI4]3−(649 ppm, using the lowest excitation energy of the diatomic molecule) and [CdI4]3−(1941 ppm using the lowest excitation energy of the diatomic molecule), is evaluated.

  在水溶液中，获得了 CuX-KX 系统（其中 X=Cl、Br、I）的 63Cu 化学屏蔽顺序（[CuCl4]3- （simeq[CuBr4]3-<[CuI4]3-）和线宽（10 至 30 kHz）。利用平均激发能量近似的扰动理论，[CuCl4]3- 和 [Cu(CN)4]3- 之间的化学位移（-694 ppm）可以用顺磁项来解释，该顺磁项主要取决于 Cu（I）原子上的 3d 空穴。在水溶液中，Cu(I) 卤化物配合物的线宽主要由 Cu(I) 核四极与电场梯度的相互作用来解释，而电场梯度是由 Cu 原子上的 3d 孔产生的。针对[MX4](4-i)-（[MCl4](4-i)-≤[MBr4](4-i)-<[MI4](4-i)-）金属屏蔽顺序的异常递增，评估了重原子效应在[CuI4]3-（649 ppm，使用二原子分子的最低激发能）和[CdI4]3-（1941 ppm，使用二原子分子的最低激发能）金属屏蔽中的可能性。
• Combination therapy
  申请人：——

  公开号：US20040102360A1

  公开（公告）日：2004-05-27

  The present invention relates to methods of treating cancer using a combination of at least two Akt inhibitors or a compound which is an inhibitor of Akt and an inhibitor of a protein kinase, which methods comprise administering to a mammal, either sequentially in any order or simultaneously, amounts of at least two therapeutic agents selected from a group consisting of a compound(s) which are inhibitors of Akt and compound(s) which are inhibitors of protein kinases. The invention also relates to methods of preparing such compositions.

  本发明涉及使用至少两种Akt抑制剂或一种Akt抑制剂和一种蛋白激酶抑制剂的组合物治疗癌症的方法，其中的方法包括向哺乳动物施用来自以下组合中至少两种治疗剂量的治疗剂：一种是Akt抑制剂，另一种是蛋白激酶抑制剂，可以顺序或同时施用。本发明还涉及制备这种组合物的方法。
• Method of treating cancer
  申请人：——

  公开号：US20040106540A1

  公开（公告）日：2004-06-03

  The present invention is directed to a method of treating cancer which comprises administration of a compound which selectively inhibits the activity of one or two of the isoforms of Akt, a serine/threonine protein kinase. The invention is particularly directed to the method wherein the compound is dependent on the presence of the plestrin homology domain of Akt for its inhibitory activity.

  本发明涉及一种治疗癌症的方法，包括给予一种选择性抑制一种或两种Akt异构体（一种丝氨酸/苏氨酸蛋白激酶）活性的化合物。本发明特别涉及一种方法，其中所述化合物的抑制活性依赖于Akt的plestrin同源结构域的存在。
• Piperazine derivatives
  申请人：Daiichi Pharmaceutical Co., Ltd.

  公开号：US05681954A1

  公开（公告）日：1997-10-28

  A compound represented by formula (I): ##STR1## wherein Q represents an aryl group, a heterocyclic group, a diarylmethyl group, an aralkyl group composed of an aryl group and an alkylene group, an alkyl group or a cycloalkyl group, in which the aryl group, heterocyclic group, and the aryl moiety of the diarylmethyl group and aralkyl group may be substituted with one or more substituents; R represents a bicyclic, substituted, nitrogen-containing heterocyclic group or a substituted phenyl group, in which the nitrogen-containing heterocyclic group is composed of a 5-membered, substituted, aromatic or saturated ring containing one or two nitrogen atoms and a 6-membered ring; and Z represents an alkylene group, an alkenylene group, an alkylene group, a carbonyl group, an alkylene group containing a carbonyl group or an oxalyl group, or a salt thereof. The compound has calmodulin inhibitory activity and is useful as a treating agent for diseases in the circulatory organs or in the cerebral region which are caused by excessive activation of calmodulin.

  化合物的化学式为(I)：##STR1## 其中Q代表芳基，杂环基，二芳基甲基基团，由芳基和烷基组成的芳基烷基基团，烷基或环烷基，在其中，芳基，杂环基和二芳基甲基基团和芳基烷基基团的芳基部分可以被一个或多个取代基取代。R代表双环取代氮杂环基或取代苯基，其中氮杂环基由一个五元取代芳香或饱和环和一个六元环组成，其中含有一个或两个氮原子；Z代表烷基，烯基，含有羰基的烷基，含有羰基的烷基或草酰基，或其盐。该化合物具有钙调蛋白抑制活性，并可用作治疗循环器官或脑部区域疾病的治疗剂，这些疾病是由于钙调蛋白过度活化引起的。